“医疗器械一哥”，拟赴港上市！

Core Viewpoint - Mindray Medical plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy and capital strength [1][2] Group 1: H-Share Issuance - The company announced the issuance of H-shares and listing on the Hong Kong Stock Exchange after a board meeting on October 14 [2] - The maximum number of H-shares to be issued will not exceed 10% of the total share capital post-issuance, with an additional 15% overallotment option [2][3] - The issuance is subject to approval from shareholders and regulatory bodies, with significant uncertainties regarding final implementation [3] Group 2: Financial Performance - For the first half of 2025, Mindray Medical reported revenues of 16.743 billion yuan, a year-on-year decline of 18.45%, and a net profit of 5.069 billion yuan, down 32.96% year-on-year [3] Group 3: Shareholder Actions - The controlling shareholder, Magnifice (HK) Limited, has pledged 4.4 million shares, representing 1.48% of its holdings and 0.36% of the total share capital [4] - As of the announcement date, the total pledged shares by the controlling shareholder and its concerted parties amount to 35.15 million shares, or 5.63% of their holdings and 2.90% of the total share capital [4] Group 4: Corporate Governance Changes - The board of directors approved changes in governance structure, including the appointment of a new independent director, Gu Minkang, effective upon the H-share listing [5] - The board's nomination committee will also undergo changes to align with the new governance structure [5] Group 5: Market Position - As of October 14, Mindray Medical's stock price was 230.68 yuan per share, with a total market capitalization of 279.7 billion yuan [6]